Drug intelligence / Profile preview

REM0045392

Development stage: Phase 1
Lead developer: reMYND
Modality: Small Molecules
Administration: Oral

Overview

REM0045392 is an investigational small molecule drug developed by reMYND NV for the treatment of **Alzheimer's disease**. It is currently in Phase 1 clinical trials, where its safety, tolerability, pharmacokinetics, and pharmacodynamics are being evaluated in healthy adults and elderly subjects. The drug is being developed specifically for nervous system diseases, with Alzheimer’s disease as its primary active indication. While the exact mechanism of action and molecular target(s) have not been disclosed, reMYND NV is known to focus research on pathways relating to cellular dysfunction in neurodegenerative diseases[1][3][4][5].

Other names: REM0045392REM-0045392REM 0045392

Targets

SEPT (Septin protein complex)MAPT (Microtubule-associated protein tau)

Beyond the preview

Go deeper on REM0045392.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REM0045392.

Explore the full profile